Mercury Laboratories Limited

BSE:538964 Stock Report

Market Cap: ₹1.1b

Mercury Laboratories Past Earnings Performance

Past criteria checks 4/6

Mercury Laboratories has been growing earnings at an average annual rate of 6%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 5.8% per year. Mercury Laboratories's return on equity is 7.7%, and it has net margins of 5.8%.

Key information

6.0%

Earnings growth rate

6.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate5.8%
Return on equity7.7%
Net Margin5.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Mercury Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:538964 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24694401660
30 Jun 24739501460
31 Mar 24756571590
31 Dec 23776411530
30 Sep 23767351530
30 Jun 23761511450
31 Mar 23753561470
31 Dec 22692621360
30 Sep 22686611400
30 Jun 22600391290
31 Mar 22579361250
31 Dec 21624341210
30 Sep 21653491150
30 Jun 21708561030
31 Mar 21686531080
31 Dec 2062643970
30 Sep 2059638960
30 Jun 2055932930
31 Mar 2057332940
31 Dec 1957638890
30 Sep 1959533860
30 Jun 19572301000
31 Mar 1955528780
31 Dec 1856330770
30 Sep 1852633750
30 Jun 1854342740
31 Mar 1851920730
31 Dec 1752322760
30 Sep 17490121100
30 Jun 174614740
31 Mar 1748027750
31 Dec 1645027710
30 Sep 1647136720
30 Jun 1647538720
31 Mar 1647739770
31 Dec 1546240710
30 Sep 1543335690
30 Jun 1543435670
31 Mar 1541333640
31 Dec 1443629610
30 Sep 1443932600
30 Jun 1442432590
31 Mar 1441632570
31 Dec 1338535570

Quality Earnings: 538964 has high quality earnings.

Growing Profit Margin: 538964's current net profit margins (5.8%) are higher than last year (4.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 538964's earnings have grown by 6% per year over the past 5 years.

Accelerating Growth: 538964's earnings growth over the past year (14.6%) exceeds its 5-year average (6% per year).

Earnings vs Industry: 538964 earnings growth over the past year (14.6%) did not outperform the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 538964's Return on Equity (7.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mercury Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shailaja CH.FirstCall Research